Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001104659-25-016592·Aardvark Therapeutics, Inc.
Schedule 13G ownership disclosure
Aardvark Therapeutics Inc
Common Stock, par value $0.00001 per share (the "Shares") · CUSIP: 002942100
Event date: 2025-02-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Citadel Advisors LLC
Shares: 1,152,375.00 · Class: 5.4%
- Citadel Advisors Holdings LP
Shares: 1,152,375.00 · Class: 5.4%
- Citadel GP LLC
Shares: 1,152,375.00 · Class: 5.4%
- Citadel Securities LLC
Shares: 40,596.00 · Class: 0.2%
- Citadel Securities Group LP
Shares: 40,596.00 · Class: 0.2%
- Citadel Securities GP LLC
Shares: 40,596.00 · Class: 0.2%
- Kenneth Griffin
Shares: 1,192,971.00 · Class: 5.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-016592
- Form type
- SCHEDULE 13G
- Filer
- Aardvark Therapeutics, Inc.
- CIK
- CIK 1774857
- Filed
- Feb 24, 2025
- Reporting period
- Feb 14, 2025
- Description
- Schedule 13G beneficial ownership